Consensus Mirum Pharmaceuticals, Inc.

Stocks

MIRM

US6047491013

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-28 EDT			5-day change	1st Jan Change
85.81 ^USD	+0.29%		+2.84%	+8.63%

10-26	Mirum Pharmaceuticals, Inc. Announces Positive Results From Cohort 2 Of The Pivotal PROGRESS Study Of ATEBRIOZ In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva	CI
10-26	Mirum Drug Shows Promise Against Abnormal Bone Growth in Pediatric Phase 2 Trial	MT

Evolution of the Average Target: Mirum Pharmaceuticals, Inc.

Evolution of the Target Price: Mirum Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Mirum Pharmaceuticals, Inc.

88fc755eb5b1c6cf.D9mndaXYi9KOJQMURurGvzulOgdro9qFdoXGHrezBB8.Tpr1JNKrypPJHTJlBIisyVKVUEEYjp3UBOGWZvqDPVQ4ifUD7p7DmuoIbA~cf85a86eff2aa928350e339bbf2199ff

Analysts' recommendations: Mirum Pharmaceuticals, Inc.

10-08	RBC Raises Price Target on Mirum Pharmaceuticals to $155 From $135, Keeps Outperform Rating	MT
08-06	RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating	MT
07-07	RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating	MT
05-19	Wolfe Research Initiates Mirum Pharmaceuticals With Outperform Rating	MT
05-07	RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $142 From $128, Maintains Outperform Rating	MT
05-04	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
02-26	RBC Lowers Price Target on Mirum Pharmaceuticals to $128 From $130, Keeps Outperform Rating	MT
02-26	Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $130 From $123, Keeps Overweight Rating	MT
02-18	Mirum Can Sustain Revenue Growth with Multiple Catalysts, RBC Says	MT
01-12	Baird Adjusts Mirum Pharmaceuticals Price Target to $95 From $88, Maintains Outperform Rating	MT
12-09	Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says	MT
12-09	Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating	MT
25-10-16	Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $81 From $75, Keeps Overweight Rating	MT
25-09-24	TD Cowen Initiates Mirum Pharmaceuticals at Buy With $95 Price Target	MT
24-08-26	Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating	MT
24-07-30	Sobi fell after rumors of Mirum takeover - unlikely deal according to Ålandsbanken	FW
24-06-20	Stifel Adjusts Mirum Pharmaceuticals Price Target to $66 From $48, Maintains Buy Rating	MT
24-06-18	Evercore ISI Adjusts Price Target on Mirum Pharmaceuticals to $62 From $53, Maintains Outperform Rating	MT
24-06-18	Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $71 From $60, Maintains Strong Buy Rating	MT
24-06-18	Citigroup Adjusts Price Target on Mirum Pharmaceuticals to $64 From $38, Maintains Buy Rating	MT
24-06-18	JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating	MT
24-06-18	Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $57 From $53, Maintains Overweight Rating	MT
24-06-18	JPMorgan Adjusts Price Target on Mirum Pharmaceuticals to $39 From $31, Maintains Overweight Rating	MT
24-06-17	Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $50 From $45, Maintains Overweight Rating	MT
24-06-17	Baird Adjusts Mirum Pharmaceuticals Price Target to $39 From $34, Maintains Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MIRUM PHARMACEUTICALS, INC.					+78.8%
	ELI LILLY AND COMPANY					+3.53%
	JOHNSON & JOHNSON					+3.09%
	ABBVIE INC.					-0.98%
	ROCHE HOLDING AG					-2.95%
	MERCK & CO., INC.					+13.36%
	NOVARTIS AG					-1.36%
	ASTRAZENECA PLC					+23.73%
	AMGEN INC.					-12.06%
	GILEAD SCIENCES, INC.					+0.62%
	Average					+10.58%
	Weighted average by Cap.					+3.10%